

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Hansoh Pharmaceutical Group Company Limited

翰森製藥集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3692)

VOLUNTARY ANNOUNCEMENT

THE PHASE III CLINICAL STUDY OF HS-20093 IN THE TREATMENT OF OSTEOSARCOMA HAS MET THE PRIMARY ENDPOINT

The board of directors (the “**Board**”) of Hansoh Pharmaceutical Group Company Limited (the “**Company**” and together with its subsidiaries, the “**Group**”) is pleased to announce that HS-20093, the Group’s proprietary B7-H3 directed antibody-drug conjugate (ADC), met the primary endpoint in a pivotal Phase III clinical trial (ARTEMIS-011) for patients with osteosarcoma who had progressed or relapsed after at least two prior lines of systemic therapy. Compared with chemotherapy, HS-20093 demonstrated a statistically significant and clinically meaningful progression-free survival (“**PFS**”) improvement as assessed by the independent review committee (IRC). Consistent benefits were also observed across secondary clinical endpoints, including overall survival (OS) and investigator-assessed PFS. The safety profile was consistent with prior findings, and no new safety signals were identified.

Based on these positive results, the Group will initiate communications with the relevant regulatory authority to advance preparations for a biologics license application in China in the near term. The detailed data from the ARTEMIS-011 study is expected to be presented at an upcoming international oncology congress.

By Order of the Board
Hansoh Pharmaceutical Group Company Limited
Zhong Huijuan
Chairlady

Hong Kong, July 28, 2026

As at the date of this announcement, the Board comprises Ms. Zhong Huijuan as chairlady and executive director, Ms. Sun Yuan and Dr. Lyu Aifeng as executive directors, and Mr. Lin Guoqiang, Mr. Chan Charles Sheung Wai, Ms. Yang Dongtao and Mr. Yan Jia as independent non-executive directors.